DG DISPATCH - APSS: Switch To Modafinil Benefits Patients With Narcolepsy
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




DG DISPATCH - APSS: Switch To Modafinil Benefits Patients With Narcolepsy

By Jill Stein
Special to DG News

LAS VEGAS, NV -- June 20, 2000 -- New findings indicate that the wake-promoting agent modafinil significantly improves symptoms of excessive daytime sleepiness (EDS) in patients with narcolepsy who do not respond to treatment with central nervous system (CNS) stimulants commonly used to treat EDS.

The results were presented at the 14th Annual Meeting of the Associated Professional Societies by Dr. Jonathan Schwartz, of Integris Southwest and Baptist Medical Centers in Oklahoma City, OK.

The trial included 151 patients with narcolepsy, 18 to 65 years of age, who had been unsatisfactorily treated for EDS with dextroamphetamine, methylphenidate or pemoline. Prior treatment was considered unsatisfactory because of low tolerability, tolerance, abuse, dependence, patient dissatisfaction or the need for a drug holiday.

After a two-week washout period, all patients received once daily modafinil, 200 mg, for one week. At the beginning of week 2, the investigator could increase the modafinil dose to 400 mg per day. During weeks 3 though 6, patients received their optimal dose of modafinil (either 200 mg or 400 mg per day).

Efficacy was assessed by the Epworth Sleepiness Scale (ESS) at baseline and at weeks 1, 2, and 6.

Approximately 70 percent of the patients were taking 400 mg modafinil daily, and 21 percent were taking 200 mg modafinil daily during weeks two through six, Dr. Schwartz said.

The mean ESS scores were significantly improved from baseline as early as week 1 and improvements in EDS were maintained throughout the study regardless of the stimulant previously received. After six weeks of treatment with modafinil, 79 percent of the patients were rated by the investigators as clinically improved and 62 percent were rated as "much improved" or "very much improved."

Results also showed that modafinil treatment was well tolerated.

Related Link: modafinil (Provigil).

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities